Susquehanna International Group, LLP Ascendis Pharma A/S Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $7.41 Million - $10.1 Million	65,600 Added 75.75%	152,200 $22.7 Million
Q2 2024 Aug 15, 2024	BUY	$121.07 - $153.67 $3.22 Million - $4.09 Million	26,600 Added 44.33%	86,600 $11.8 Million
Q1 2024 May 07, 2024	BUY	$123.45 - $159.4 $1.36 Million - $1.75 Million	11,000 Added 22.45%	60,000 $9.07 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $688,800 - $1.02 Million	-8,000 Reduced 14.04%	49,000 $6.17 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $3.79 Million - $4.55 Million	-43,800 Reduced 43.45%	57,000 $5.34 Million
Q2 2023 Aug 11, 2023	BUY	$69.96 - $97.84 $4.9 Million - $6.85 Million	70,000 Added 227.27%	100,800 $9 Million
Q1 2023 May 16, 2023	SELL	$104.9 - $126.78 $1.22 Million - $1.47 Million	-11,600 Reduced 27.36%	30,800 $3.3 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $3.1 Million - $4.12 Million	31,200 Added 278.57%	42,400 $5.18 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $344,523 - $451,943	-4,100 Reduced 26.8%	11,200 $1.16 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.